• Hakkımızda
  • Künye / İletişim
  • Kullanım Koşulları
Pharma Turkey
Beauty İstanbul
  • Anasayfa
  • Güncel
  • İlaç
  • Sağlık
  • Söyleşi
  • ATAMA
  • E-Dergi
  • ENGLISH
No Result
View All Result
  • Anasayfa
  • Güncel
  • İlaç
  • Sağlık
  • Söyleşi
  • ATAMA
  • E-Dergi
  • ENGLISH
No Result
View All Result
Pharma Turkey
No Result
View All Result
Home ENGLISH

Optimisation of paperboard can cut the carbon footprint of pharmaceutical packaging by 60%, based on life cycle assessment

by editor
07 Mart 2024
in ENGLISH
0
Optimisation of paperboard can cut the carbon footprint of pharmaceutical packaging by 60%, based on life cycle assessment

Pharmaceutical product packaging accounts for a large part of manufacturers’ Scope 3 emissions, which consider, for example raw material production, manufacturing, and end-of-life disposal. According to Metsä Board studies, fresh fibre paperboard can notably reduce the carbon footprint of pharmaceutical packaging by optimising the paperboard in use.  

Assessments* conducted by Metsä Board demonstrate the significant carbon footprint reductions that pharmaceutical manufacturers can achieve by switching from commonly used grades to Metsä Board fresh fibre paperboards. Switching from a solid bleached board (SBB) to Metsä Board folding boxboard can reduce the carbon footprint of packaging by over 50%, and replacing white lined chipboard (WLC) with Metsä Board folding boxboard can result in a 60% reduction or even higher. These assessments have been verified by IVL Swedish Environmental Research Institute. The technical background report and the verification statement are available on Metsä Board’s website.

The lower carbon footprint of Metsä Board’s folding boxboards, compared to the above mentioned boards, is due to the use of fossil free energy in their production and their lighter weight. However, despite the lighter weight, Metsä Board’s folding boxboards still retain the durability and functional properties of traditional heavier grades.

“As a responsible materials supplier it is our job to provide pharma brand owners with transparent, unbiased information that helps them evaluate packaging materials to make better-informed and sustainable choices to reduce their carbon footprint,” says Anne Uusitalo, Product Safety and Sustainability Director at Metsä Board. Metsä Board provides accurate information about the carbon footprint of its paperboard products and can also provide full life cycle assessments to its customers.

*) Assessments follow procedural and methodological requirements of ISO 14025 and are consistent with ISO 14040 and 14044 standards. The selected system boundary for the study was cradle-to-gate + end-of-life and selected climate change impact methodology was EF3.1 Climate Change – total. Climate change impacts for competing materials utilises data from Sphera LCA for Packaging which seeks to represent general products in the European market. The technical background report and the verification statement are available on Metsä Board’s website.

 

Tags: Anne UusitalodisposalMetsä Board’s websitePharmaceuticalPharmaceutical productProduct Safety and Sustainability Director at Metsä BoardtechnicalWLC
Previous Post

New clinical study to evaluate QuickMIC® in the diagnostic workflow of urosepsis

Next Post

Orzaks İlaç, 8 Mart Dünya Kadınlar Günü’nde #İlhamAlGüçVer projesiyle farkındalık oluşturdu

editor

Next Post
Orzaks İlaç, 8 Mart Dünya Kadınlar Günü’nde #İlhamAlGüçVer projesiyle farkındalık oluşturdu

Orzaks İlaç, 8 Mart Dünya Kadınlar Günü’nde #İlhamAlGüçVer projesiyle farkındalık oluşturdu

E-dergi

  • Hakkımızda
  • Künye / İletişim
  • Kullanım Koşulları

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Anasayfa
  • Güncel
  • İlaç
  • Söyleşi
  • ATAMA
  • E-Dergi
  • ENGLISH

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.